Second-Line Therapy Options in Metastatic Renal Cell Carcinoma

Video

This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles.

In this video, Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations of the different toxicity profiles.

Agarwal spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.